Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment

P. Russo, A. Cesario, S. Rutella, G. Veronesi, L. Spaggiari, D. Galetta, S. Margaritora, P. Granone, D. S. Greenberg

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Nicotine dependence (ND) is one of the world's leading causes of preventable death. Nicotine addiction and other forms of drug addiction continue to be significant public health problems in the world. Evidence for a genetic influence on smoking behaviour and ND has prompted a search for susceptibility genes. Evidence has recently accumulated that single nucleotide polymorphisms (SNPs) in the genetic region encoding the nicotinic acetylcholine receptor (nAChR) subunits α6, α5, α3, and β4 are associated with smoking and ND. Brain nAChR are a heterogeneous family of ion channels expressed in the various parts of the brain. A number of studies suggest that brain nAChR are critical targets for the development of pharmacotherapy for nicotine and other drug addictions. In this review, we will discuss the nAChR subtypes, their function in response to endogenous brain transmitters, and how their functions are regulated in the presence of nicotine. Additionally, we will provide an overview of the three major pharmacotherapies for smoking cessation (which have demonstrated efficacy) such as: nicotine replacement therapy (NRT), bupropion, and varenicline. An appreciation of the complexity of nAChR and their regulation will be necessary for the development of nAChR modulators as potential pharmacotherapy for drug addiction. Prevention strategies should be tailored to carriers of SNPs located on chromosome 15q and that are strongly associated with nicotine dependence and risk of lung cancer.

Original languageEnglish
Pages (from-to)91-112
Number of pages22
JournalCurrent Medicinal Chemistry
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Withholding Treatment
Nicotinic Receptors
Smoking Cessation
Nicotine
Tobacco Use Disorder
Drug therapy
Substance-Related Disorders
Brain
Drug Therapy
Single Nucleotide Polymorphism
Smoking
Polymorphism
Bupropion
Nucleotides
Pharmaceutical Preparations
Ion Channels
Cause of Death
Lung Neoplasms
Public health
Chromosomes

Keywords

  • Bupropion
  • Genetic variants
  • Nicotine-addiction
  • Nicotinic receptor
  • Varenicline

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment. / Russo, P.; Cesario, A.; Rutella, S.; Veronesi, G.; Spaggiari, L.; Galetta, D.; Margaritora, S.; Granone, P.; Greenberg, D. S.

In: Current Medicinal Chemistry, Vol. 18, No. 1, 01.2011, p. 91-112.

Research output: Contribution to journalArticle

@article{1f598eda21af4d11a70c8dacf91693c1,
title = "Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment",
abstract = "Nicotine dependence (ND) is one of the world's leading causes of preventable death. Nicotine addiction and other forms of drug addiction continue to be significant public health problems in the world. Evidence for a genetic influence on smoking behaviour and ND has prompted a search for susceptibility genes. Evidence has recently accumulated that single nucleotide polymorphisms (SNPs) in the genetic region encoding the nicotinic acetylcholine receptor (nAChR) subunits α6, α5, α3, and β4 are associated with smoking and ND. Brain nAChR are a heterogeneous family of ion channels expressed in the various parts of the brain. A number of studies suggest that brain nAChR are critical targets for the development of pharmacotherapy for nicotine and other drug addictions. In this review, we will discuss the nAChR subtypes, their function in response to endogenous brain transmitters, and how their functions are regulated in the presence of nicotine. Additionally, we will provide an overview of the three major pharmacotherapies for smoking cessation (which have demonstrated efficacy) such as: nicotine replacement therapy (NRT), bupropion, and varenicline. An appreciation of the complexity of nAChR and their regulation will be necessary for the development of nAChR modulators as potential pharmacotherapy for drug addiction. Prevention strategies should be tailored to carriers of SNPs located on chromosome 15q and that are strongly associated with nicotine dependence and risk of lung cancer.",
keywords = "Bupropion, Genetic variants, Nicotine-addiction, Nicotinic receptor, Varenicline",
author = "P. Russo and A. Cesario and S. Rutella and G. Veronesi and L. Spaggiari and D. Galetta and S. Margaritora and P. Granone and Greenberg, {D. S.}",
year = "2011",
month = "1",
doi = "10.2174/092986711793979715",
language = "English",
volume = "18",
pages = "91--112",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment

AU - Russo, P.

AU - Cesario, A.

AU - Rutella, S.

AU - Veronesi, G.

AU - Spaggiari, L.

AU - Galetta, D.

AU - Margaritora, S.

AU - Granone, P.

AU - Greenberg, D. S.

PY - 2011/1

Y1 - 2011/1

N2 - Nicotine dependence (ND) is one of the world's leading causes of preventable death. Nicotine addiction and other forms of drug addiction continue to be significant public health problems in the world. Evidence for a genetic influence on smoking behaviour and ND has prompted a search for susceptibility genes. Evidence has recently accumulated that single nucleotide polymorphisms (SNPs) in the genetic region encoding the nicotinic acetylcholine receptor (nAChR) subunits α6, α5, α3, and β4 are associated with smoking and ND. Brain nAChR are a heterogeneous family of ion channels expressed in the various parts of the brain. A number of studies suggest that brain nAChR are critical targets for the development of pharmacotherapy for nicotine and other drug addictions. In this review, we will discuss the nAChR subtypes, their function in response to endogenous brain transmitters, and how their functions are regulated in the presence of nicotine. Additionally, we will provide an overview of the three major pharmacotherapies for smoking cessation (which have demonstrated efficacy) such as: nicotine replacement therapy (NRT), bupropion, and varenicline. An appreciation of the complexity of nAChR and their regulation will be necessary for the development of nAChR modulators as potential pharmacotherapy for drug addiction. Prevention strategies should be tailored to carriers of SNPs located on chromosome 15q and that are strongly associated with nicotine dependence and risk of lung cancer.

AB - Nicotine dependence (ND) is one of the world's leading causes of preventable death. Nicotine addiction and other forms of drug addiction continue to be significant public health problems in the world. Evidence for a genetic influence on smoking behaviour and ND has prompted a search for susceptibility genes. Evidence has recently accumulated that single nucleotide polymorphisms (SNPs) in the genetic region encoding the nicotinic acetylcholine receptor (nAChR) subunits α6, α5, α3, and β4 are associated with smoking and ND. Brain nAChR are a heterogeneous family of ion channels expressed in the various parts of the brain. A number of studies suggest that brain nAChR are critical targets for the development of pharmacotherapy for nicotine and other drug addictions. In this review, we will discuss the nAChR subtypes, their function in response to endogenous brain transmitters, and how their functions are regulated in the presence of nicotine. Additionally, we will provide an overview of the three major pharmacotherapies for smoking cessation (which have demonstrated efficacy) such as: nicotine replacement therapy (NRT), bupropion, and varenicline. An appreciation of the complexity of nAChR and their regulation will be necessary for the development of nAChR modulators as potential pharmacotherapy for drug addiction. Prevention strategies should be tailored to carriers of SNPs located on chromosome 15q and that are strongly associated with nicotine dependence and risk of lung cancer.

KW - Bupropion

KW - Genetic variants

KW - Nicotine-addiction

KW - Nicotinic receptor

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=78751485017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751485017&partnerID=8YFLogxK

U2 - 10.2174/092986711793979715

DO - 10.2174/092986711793979715

M3 - Article

VL - 18

SP - 91

EP - 112

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 1

ER -